PainReform Ltd - PRFX Price Chart

PainReform Ltd. (PRFX) has developed an advanced method for long-term postoperative pain management that minimizes the use of opioids. The high value of the PRF-110 drug is driven by its oil-based composition, which provides an effect for up to three days, ensuring stable demand from clinics. Intellectual property protection helps the brand avoid dumping and maintain profitability. The indicator is 0.74. This chart illustrates the asset's market price.

PRFX - painreform.com Quote Chart over the range 07/04/2022 - 11/12/2026

PainReform Ltd - analytical breakdowns and key metrics (PRFX)

- stock value and consensus price forecast:

Price Chart PainReform Ltd.|PRFX - Forecast Levels Chart

- issuer market value details:

Market Value PainReform Ltd|PRFX - Value Adjusted for Debt and Cash

- balance sheet equity data:

Book Value per Share PainReform|PRFX - Net Asset Value|Market Cap to Net Assets Ratio painreform.com|PRFX - Total Business Assets

- debt burden and liquidity indicators:

- earnings and market ratios statistics:

PRFX - Net Income|Projected Future Earnings PainReform Ltd.|PRFX - P/E Multiple|Projected Price to Earnings PainReform|PRFX - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PainReform Ltd|PRFX - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months PainReform|PRFX - Earnings per share for the last four quarters|Quarterly EPS earnings growth painreform.com|PRFX - Earnings per share increase in current year|Earnings growth forecast for next year PainReform Ltd.

Fundamental valuation:PainReform Ltd.

The price reflects the current market value of a single share, serving as a key criterion for compliance with US exchange listing requirements to ensure asset liquidity. Professional investors track the asset's price movements as an indicator of speculative expectations, as the absence of commercial products at PainReform Ltd. (PRFX) makes quotes dependent on test results and the rate of investment capital burn.

Analysis of competing companies